	US 11,872,268 B2
	Safe and effective beta-lactamase dosing for microbiome protection
Joseph Sliman, Rockville, MD (US)
Assigned to Theriva Biologics, Inc., Rockville, MD (US)
Filed by Theriva Biologics, Inc., Rockville, MD (US)
Filed on Jan. 10, 2022, as Appl. No. 17/572,055.
Application 17/572,055 is a continuation of application No. 16/892,647, filed on Jun. 4, 2020, granted, now 11,253,577.
Application 16/892,647 is a continuation of application No. 15/062,559, filed on Mar. 7, 2016, granted, now 10,709,773, issued on Jul. 14, 2020.
Claims priority of provisional application 62/260,979, filed on Nov. 30, 2015.
Claims priority of provisional application 62/167,006, filed on May 27, 2015.
Claims priority of provisional application 62/129,199, filed on Mar. 6, 2015.
Prior Publication US 2022/0125895 A1, Apr. 28, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/50 (2006.01); A61K 31/546 (2006.01); A61K 45/06 (2006.01); A61K 9/50 (2006.01)

CPC A61K 38/50 (2013.01) [A61K 9/5026 (2013.01); A61K 9/5078 (2013.01); A61K 31/546 (2013.01); A61K 45/06 (2013.01); C12Y 305/02006 (2013.01)]

8 Claims

1. A method of protecting a human patient's gastrointestinal microbiome, comprising administering an effective amount of a pharmaceutical composition comprising a beta-lactamase to a patient in need thereof, wherein:

the patient is undergoing treatment or has recently undergone treatment with a beta-lactam antibiotic, wherein the beta-lactam antibiotic is a penicillin or a cephalosporin;

the patient is undergoing treatment with a proton pump inhibitor, wherein the proton pump inhibitor is esomeprazole, omeprazole, lansoprazole, rabeprazole, pantoprazole, or dexlansoprazole; and

the beta-lactamase comprises an amino acid sequence having at least 98% identity with SEQ ID NO: 1.